June 27, 2014

Ohm Labs, a wholly owned subsidiary of Ranbaxy Labs, on Friday announced that it received approval from the Food and Drug Administration to manufacture and market valsartan tablets in 40 mg, 80 mg, 160 mg and 320 mg dosage strengths.

June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

June 17, 2014

Novartis on Tuesday announced that it had submitted a biologic license application to the Food and Drug Administration for marketing approval for the use of Bexsero.

May 16, 2014

These are interesting times to be in the OTC business, Matt Mannelly, Prestige Brands president and CEO, told analysts Thursday.

May 15, 2014

Teva Pharmaceutical was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis, drug 10 days before the patent on the medication expires, according to a Bloomberg report published Thursday morning.

May 9, 2014

CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis.

April 22, 2014

Following a multifaceted deal with Novartis on Tuesday, GlaxoSmithKline and Novartis have created a consumer healthcare giant with annual worldwide revenues of $11 billion on a 2013 pro forma basis.

April 22, 2014

Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

April 3, 2014

U.S. retail sales of pet medications reached $8 billion in 2013, including sales through veterinarians, brick-and-mortar retailers and online according to a Packaged Facts report released Wednesday.

April 2, 2014

Sandoz on Tuesday announced the U.S. market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex Ointment.

March 13, 2014

More Americans are more often seeking their ounce of prevention. According to Bain & Co.’s recent Healthy Living Survey, 75% of consumers are in pursuit of a healthier lifestyle. Take that predominant mindset, coupled with the outcomes-driven preventive focus associated with the Affordable Care Act, and you have a formula for OTC success at retail pharmacy.

February 18, 2014

Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

February 7, 2014

Novartis Consumer Health on Thursday announced that Todd Hutsko has been appointed head of sales U.S., effective March 1.

February 6, 2014

Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol.

January 30, 2014

Novartis Consumer Health will be relaunching Theraflu for the 2014-2015 cough-cold season, Brian McNamara, Novartis division head OTC, told analysts.

January 14, 2014

Drug maker Sandoz has started a late-stage clinical trial of a biotech drug used to treat autoimmune disorders, the company said.

January 9, 2014

Novartis AG is reportedly in talks with Merck to swap its animal health and vaccines businesses for Merck’s OTC business, which includes the Coppertone sunscreen and Claritin allergy medicine brands, according to a Bloomberg report.

January 9, 2014

Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.

December 16, 2013

A drug made by Novartis extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.

December 9, 2013

Swiss drug maker Novartis is providing a vaccine to Princeton University amid an outbreak of potentially fatal meningitis that has affected at least eight students, the university said Monday.

December 2, 2013

Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

November 22, 2013

Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.

November 22, 2013

Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.